Mandate

Acquisition of Alvedon approved

April 07, 2009

The Swedish Competition Authority has, following an in-depth investigation, on 3 April 2009 cleared GlaxoSmithKline’s acquisition of a portfolio of drugs, including i.a. the brand Alvedon, from AstraZeneca.

Alvedon is the leading painkiller brand in Sweden. GlaxoSmithKline controlled already prior to the acquisition Panodil, one of the main competing brands. The transaction was notified by the parties on 22 December 2008.
The Competition Authority carried out an extensive market investigation and retained external expertise to simulate the effects of the combination.

“Although the transaction involved a strong market position in painkillers based on paracetamol, the Competition Authority could eventually conclude that the transaction did not significantly impede the existence or development of effective competition. The Competition Authority’s decision is, of course, satisfactory for the parties but also of principle importance”, says Johan Karlsson, responsible partner for Vinge’s competition team, who acted for AstraZeneca.

“It is one of the few cases where efficiencies made a real difference for the outcome. The decision also shows that the Competition Authority, which it should do, could also take into account future changes in the market place, in this case the liberalization of the pharmaceutical market.”

Vinge advised AstraZeneca. Vinge’s competition team included Johan Karlsson (responsible partner), Mattias Ganslandt (economist), Per Karlsson (counsel), Peter Alstergren (associate) and Carl Johan Sundqvist (associate).   

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025